W. Mike Heath ASHP Federal Forum

(1-001) Standardizing the Assessment of Clinical Trial Complexity for Improved Pharmacy Resource Management

(1-002) Establishing a Diabetes Self-management Training Program Within the Pharmacy Chronic Care Clinic

(1-003) Modernization of an Acute Care Productivity Model for Clinical Pharmacy Practitioners at Veteran Health Indiana

(1-004) Implementation of a Standardized System for Reverse Distribution of Medications

(1-005) Optimizing Third-Party Reimbursement for Pharmacy Revenue

(1-006) Evaluation of Inhaled Corticosteroid Prescribing for Patients with COPD within the Central Alabama Veterans Health Care System

(1-007) Adherence to Recommended Vaccinations in a Veteran Rheumatology Population: A Quality Improvement Initiative

(1-008) Evaluating Pharmacist Impact in Hepatitis C Treatment and Barriers to Treatment Completion: A Quality Improvement Initiative within the Nuka System of Care

(1-009) Safety and efficacy of GLP-1 weight loss medications in the VA for patients 75 years and older

(1-010) Evaluation of Gout Outcomes among Veterans Prescribed Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

(1-011) Impact of GLP-1 Receptor Agonists on PHQ-9 scores in Patients with Major Depressive Disorder with a Comorbidity of Type 2 Diabetes Mellitus or Obesity

(1-012) Prevalence of Veterans at risk for overbasalization and utilization of newer treatment options at a single Department of Veterans Affairs Medical Center

(1-013) Evaluation of Cardiovascular Medication Use in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) at VA Greater Los Angeles

(1-014) Piloting a Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2i) Dashboard to Improve Diabetes and Renal Outcomes

(1-015) Impact of Continuous Glucose Monitoring (CGM) on HbA1c at Veterans Affairs Central California Health Care System (VACCHCS) Primary Care Clinic

(1-016) Comparison of Mixed Hyperlipidemia Management for Veterans Enrolled in a Specialty Pharmacist-Managed Lipid Clinic versus Usual Care

(1-017) Pharmacist Involvement and Weight-loss Outcomes in Veterans Prescribed Anti-Obesity Medications at the VA Eastern Colorado Healthcare System

(1-018) Evaluation of Dopamine Agonists Used for Restless Legs Syndrome at the VA Connecticut Healthcare System

(1-019) Progression of Diabetic Retinopathy in Patients with Rapid A1c Lowering Using Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

(1-020) Improving Acceptance of Naloxone in Veterans with Opioid Use Disorder Utilizing a Veteran-to-Veteran Approach

(1-021) GLP-1 Agonist Based Weight Loss Medication Renewal Criteria Evaluation at the Miami Veterans Affairs Healthcare System

(1-022) Evaluating and Improving the Prescribing of Guideline-Directed Medication Therapy for Chronic Obstructive Pulmonary Disease (COPD) at the James A. Haley Veterans Hospital & Clinics

(1-023) Increasing SGLT2 Inhibitor Utilization in Patients with Type 2 Diabetes and Concurrent ASCVD or HF or CKD

(1-024) Pharmacist-Driven Optimization of Sodium-Glucose Cotransporter-2 Inhibitor Therapy While Mitigating Sulfonylurea-Associated Risks in Veterans

(1-025) Evaluating Initiation of Continuous Glucose Monitors Impact on Hemoglobin A1c In Veterans with Type 2 Diabetes in Pharmacist-Led Clinics at the Miami VA Healthcare System

(1-026) Impact of an Updated Chronic Obstructive Pulmonary Disease (COPD) Order Set and Provider Education on COPD Dashboard Metrics

(1-027) Primary Care Pharmacist-Led Initiative to Improve Bone Health and Reduce Fracture Risk in Patients with Type 2 Diabetes at Two Veterans Affairs (VA) Locations

(1-028) Deprescribing Inappropriate Sedative-Hypnotics in Older Adults at the Boise VA Medical Center (VAMC)

(1-029) Implementation of an Oncology-Primary Care Coordination Process to Manage Hyperglycemia Risk in Patients with Type 2 Diabetes and Prediabetes Across Two Veterans Affairs (VA) Locations

(1-030) Switching Patients With Obesity From Semaglutide to Tirzepatide Due to Adverse Effects

(1-031) Assessing the Impact of a Pharmacist-Led Weight Loss Medication Management Program in a Veteran Population

(1-032) Improving Tobacco Use Screenings Among Veterans at Jesse Brown Veterans Affairs Medical Center

(1-033) Assessing Effect of Transitioning from Semaglutide to Tirzepatide

(1-034) Retrospective Analysis of Urinary Tract Infections in Veterans on Empagliflozin

(1-035) Influence of Continuous Glucose Monitors and Glycemic Control in Veterans with Diabetes Mellitus at VA Central Iowa

(1-036) Association Between Adherence to Continuous Glucose Monitor and Hemoglobin A1c in Veterans

(1-037) Impact of Semaglutide versus Tirzepatide on Daily Insulin Requirements

(1-038) Evaluation of outcomes with injectable weight loss medications managed by a clinical pharmacist practitioner

(1-039) Dashboard Driven Care: Sodium Glucose Cotransporter-2 Inhibitor Utilization in Veterans with Concurrent Diabetes Mellitus, Heart Failure, Kidney Disease, and Atherosclerotic Cardiovascular Disease

(1-040) Implementation of a Pharmacist-Led Shared Medical Appointment for Weight Management at a Veterans Affairs Medical Center

(1-041) Assessing Tolerability of Switching from Maximum Dose Semaglutide to Tirzepatide for Weight Loss in the Veteran Population

(1-042) Impact of Glucagon-Like Peptide-1 Receptor Agonist (GLP1RA) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP1RA in Veterans with Type 1 Diabetes and Obesity on Insulin Pumps

(1-043) Optimization of Clinical Pharmacy Practitioner Efficiency and Veteran Satisfaction Through Cancellation Rate Analysis and CGM Class Expansion

(1-044) The Implementation and Impact of Weight Management Services within Pharmacy Primary Care

(1-045) Implementation of Indian Health Service (IHS) Asthma Control in Tribal Communities (ACT) Initiative to Improve Asthma-Related Outcomes in a Primary Care Setting

(1-046) Impact of Depression on Glycemic Variability in Veterans with Type 2 Diabetes

(1-047) Evaluation of Patient-Aligned Care Team (PACT) Clinical Pharmacist Practitioner (CPP) Monitoring of Brand Name Levothyroxine to Generic Conversion

(1-048) Developing Pharmacist-Lead, Multidisciplinary Shared Medical Appointments for Veteran Outpatients Initiating Weight Management Medications

(1-049) Impact of Clinical Pharmacist Practitioners on Testosterone Management in Primary Care

(1-050) Pharmacist-Led Urate-Lowering Therapy Optimization for Gout Management in a Veterans Health Administration Setting

(1-051) Increasing Pharmacologic Treatment for Patients with Alcohol Use Disorder through Primary Care Clinical Pharmacy Practitioner Management

(1-052) Assessing Benefit of Therapeutics for Hypertriglyceridemia: A Single Center Experience within the Indian Health Service

(1-053) Evaluating Glycemic Control in Type 2 Diabetes Patients Across Pharmacist-Led and Collaborative Care Models

(1-054) Trends in Weight and Dosing for Veteran's on Glucagon Like Peptide 1 Receptor Agonist (GLP-1RA) Therapy Beyond One Year

(1-055) Evaluating the Concordance of Continuous Glucose Monitor (CGM) Prescribing with Facility Guidelines at the Veterans Affairs Hudson Valley Health Care System (VAHVHCS)

(1-056) Optimizing Migraine Management in Veterans: A Pharmacist-Led Review of Triptan Use in Primary Care Clinics

(1-057) Assessing the Utilization and Efficacy of Semaglutide, Liraglutide, and Tirzepatide for Weight Loss in the Veteran Population

(1-058) Filtering Chronic Kidney Disease Early: Improving Stage 2 CKD Identification and Risk Factor Management in a Rural Primary Care Clinic

(1-059) Evaluation of Vitamin D Testing and Supplementation in Veterans at the Chillicothe Veterans Affairs Medical Center (VAMC)

(1-060) Tirzepatide for Diabetes and Reduction in Total Daily Dose of Insulin

(1-061) Chronic Kidney Disease Progression in Veterans on ACEI/ARB with or without Empagliflozin: A Propensity Score Matched Analysis

(1-062) Impact of Pharmacist-Led Weight Management on Outcomes in Severe Obesity

(1-063) Impact of Pharmacist-Led Antidepressant Optimization in a Tribally-Operated Primary Care Clinic

(1-065) Efficacy of Buprenorphine Transdermal Patches in Chronic Pain Treatment when Transitioning from Full Opioid Agonists.

(1-066) Effects of Continuous Glucose Monitors (CGMs) on Hemoglobin A1C Levels in Veterans with Diabetes

(1-067) Enhancing Iron Deficiency Anemia Care Through Clinic Implementation

(1-068) Evaluation of Rates of Alcohol Use Screening Among Veterans in a Primary Care Setting at the Providence VA Facility

(1-069) Medication Use Evaluation of Levothyroxine Prescribing for Initial Management of Hypothyroidism at the Veterans Affairs Providence Healthcare System

(1-070) Evaluation of Sodium-Glucose Co-Transporter 2 Inhibitor Utilization and Laboratory Monitoring at the Veterans Affairs Providence Healthcare System (VAPHS)

(1-071) Evaluation of Monitoring Processes Following Semaglutide Initiation in Patients with Type-Two Diabetes at the Columbia VA HCS

(1-072) Quality Assessment of Implementation of “Potential SGLT2 Candidate by Appointment Dashboard”, a VA Population Management Tool in the Primary Care Setting

(1-073) Implementation of Share My Health Data (SMHD) to Streamline Hypertension Care

(1-074) Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA), Glucose-Dependent Insulinotropic Polypeptide/GLP-1 RA (GIP/GLP-1RA) and Associated Gallbladder Risk in Type 2 Diabetes (T2DM)

(1-075) Expanding Access to Insulin Pump Systems in Adults with Type 2 Diabetes in a Veterans Affairs Clinical Pharmacist-Led Clinic

(1-076) Effectiveness of Tirzepatide after Inadequate Response to Semaglutide for Weight Loss: A Retrospective Analysis

(1-077) The Great D-bate: Evaluating Cholecalciferol and Ergocalciferol Once Weekly Supplementation for  Vitamin D Repletion

(1-078) STEPS (Semaglutide Therapy Efficacy and Persistence Study) Ahead

(1-079) Improving Screening for Osteoporosis and Treatment Candidacy for Veterans in Home Based Primary Care

(1-080) Investigation of Immunization Rates and Population Demographics of Vaccination Refusal

(1-081) Evidence-Based Deprescribing of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease by Pharmacists at VA Salt Lake City Healthcare System

(1-082) The Impact of VA Clinical Pharmacist Interventions on Medication Management Post-Discharge in the Transition of Care Clinic

(1-083) Optimization of GLP-1/GIP Medication Utilization within high-risk veteran populations

(1-084) Evaluation of Inhaled Corticosteroid (ICS) Prescribing Patterns in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Retrospective Chart Review

(1-085) Retrial of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Following Genitourinary Infections (GUIs) in Adults with Type 2 Diabetes Mellitus (T2DM): Impact on Recurrence and Glycemic Control

(1-086) From Nurse to Pharmacist: Improving Gaps in Interdisciplinary Hypertension Management via a Nurse-Driven Pathway

(1-087) Analyzing the impact of a formulary conversion from alogliptin to sitagliptin on Veterans at the Hershel “Woody” Williams VA Medical Center.

(1-088) Enhancing Veteran Primary Care Services Through Optimization of Clinical Pharmacist Practitioner (CPP) Staffing Ratios

(1-089) Clinical Pharmacy Practitioner Impact on Veteran Care Post-Bariatric Surgery

(1-090) Outreach to High-Risk Veterans with Lower Levels of Engagement in Tobacco Treatment Services

(1-091) Impact of Implementing a Self-Directed Care Pharmacist Role into Veteran's Affairs Patient Aligned Care Teams

(1-092) Use of Long-Acting Injectable (LAI) Mental Health Medications and Boosting Prescriber Confidence Through Targeted Education.

(1-093) Improvement of testosterone lab draw timing for biological male patients at Cheyenne Veteran Affairs Health Care System (CVAHCS).

(1-094) Deprescribing Sulfonylureas in Older Veterans with Well-Controlled Type 2 Diabetes at a Rural Veterans Affairs Health Care System

(1-095) Optimization of Guideline-Directed Medical Therapy Versus Standard of Care in Veterans Hospitalized with an Acute Heart Failure Exacerbation

(1-096) Evaluation of Prophylactic Anticoagulation usage within the Central Alabama Veterans Health Care System Inpatient setting

(1-097) Assessing Non-Receipt of Anticoagulation in High-Risk Patients with Atrial Fibrillation

(1-098) Bridging the Gap: Evaluation of Bridging Practices and Outcomes in Hospitalized Veterans on Chronic Anticoagulation Therapy

(1-099) Retrospective Review of Patients on Concomitant Direct Oral Anticoagulant (DOAC) and Antiplatelet and/or Nonsteroidal Anti-Inflammatory (NSAID) with Previously Dismissed Population Management Tool Interaction Flags

(1-100) Impact of a Pharmacist-Led Heart Failure Transition of Care Clinic on Optimization of Guideline-Directed Medical Therapy (GDMT) at James A Haley Veterans’ Hospital and Clinics

(1-101) Impact of Achieving Low-Density Lipoprotein Cholesterol Goal on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Veterans Post-Stroke

(1-102) Expanding Cardiology Pharmacists Role in Weight Management for Veterans with Heart Failure

(1-103) Optimization of Sodium-glucose Cotransporter-2 Inhibitors in Veterans with Heart Failure at the Carl Vinson VA Medical Center

(1-104) Enhancing Heart Failure Management for Veterans in a Pharmacist-Led Cardiology Clinic

(1-105) The Coprescription of Anticoagulants and Antiplatelets: An Analysis of Current Prescribing Trends at VA Maine Healthcare System

(1-106) Impact of Magnesium Sulfate Dosing on Clinical Outcomes in Emergency Department Patients with Atrial Fibrillation with Rapid Ventricular Response

(1-107) Integration of Pharmacist-Led Heart Failure Recommendations During Hospitalization

(1-108) Assessing the Safety and Appropriateness of Antiplatelet Medications in Patients on Oral Anticoagulants

(1-109) Medication Use Evaluation of the Dofetilide Ordering Process at the Harry S. Truman Memorial Veterans' Hospital

(1-110) Crow Service Unit Native Hearts Pilot Initiative to Improve Guideline-Directed Medical Therapy in American Indians/Alaska Natives with Heart Failure with Reduced Ejection Fraction

(1-111) Impact of Guideline-Directed Medical Therapy Optimization at Discharge on 90-Day Readmission Rates in Veterans with Heart Failure with Reduced Ejection Fraction

(1-112) Evaluation of Bleeding and Thromboembolism Rates with Rivaroxaban Use in an Elderly Veteran Population

(1-113) Assessing Utilization and Barriers to Guideline Directed Medical Therapy in Veterans with Heart Failure with Reduced Ejection Fraction

(1-114) Incidence of Stroke and VTE with Off-Label Dose Reduction of Apixaban for Atrial Fibrillation

(1-115) Evaluation Of Add-On Vericiguat On Hospitalizations In Veterans With Heart Failure With Reduced Ejection Fraction (HFrEF)

(1-116) Proprotein Convertase Subtilisin/Kexin Type 9 – Inhibitors Effect on LDL Lowering Over 3 Years

(1-117) Optimizing Direct-Acting Oral Anticoagulant Management Prior to Pain Procedures

(1-118) Concomitant Oral Anticoagulation and Aspirin: A Description of Current Co-Prescribing and Evaluation of Procedures at White City VA Medical Center

(1-119) Heart Failure Transitions of Care: The Impact of Pharmacists

(1-120) Evaluation of Tafamidis Prescribing and Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy at a Veterans Affairs Medical Center: A Quality Improvement Evaluation

(1-121) Outcomes of Anticoagulation Stewardship on Use of Concomitant Antiplatelets and Anticoagulants

(1-122) Comparative efficacy of sacubitril/valsartan doses on hospitalization for heart failure and mortality in a Veteran population

(1-123) Impact of a One-Time Dual Antithrombotic Review on Antiplatelet Deprescribing and Proton Pump Inhibitor (PPI) Initiation in a Veteran Population

(1-124) Use of potassium binders to optimize proteinuria therapy in patients with hypertension and chronic kidney disease

(1-125) Evaluation of Orlando Veteran Healthcare System (OVAHCS) Adherence to Guideline-Directed Medical Therapy for Patients with Chronic Kidney Disease (CKD)

(1-126) Evaluation of Methenamine Prescribing Practices on the Incidence of Urinary Tract Infections in Spinal Cord Injury Patients with Long-Term Indwelling Catheters

(1-127) Evaluating the Clinical Outcomes and Interventions Delivered During Shared Medical Appointments for Patients with COPD

(1-128) Crow Service Unit (CSU) Asthma Control in Tribal Communities Initiative Expansion: Increasing Pharmacy Managed Care Utilization to Improve Asthma Management in American Indian/Alaskan Native Adolescents

(1-129) Real-World Clinical and Cost Impacts of GLP-1 Receptor Agonists for Weight Loss in a Veteran Population

(1-130) Evaluation of Low-Dose Naltrexone (LDN) in Chronic Pain and Autoimmune Conditions at the Dayton VA Medical Center

(1-131) Impact of Budesonide-Formoterol in Treating Asthma in a Rural Setting

(1-132) Evaluation of Travoprost Prescribing and Safety in the Management of Glaucoma at VA Southern Oregon Rehabilitation Center and Clinics (SORCC)

(1-133) Evaluation of COPD Exacerbation Readmission Rates following Pharmacist-led Education on Inhaler Technique

(1-134) Assessing MOVE! as a Comprehensive Lifestyle Intervention on Weight-Loss Outcomes Among Veterans Prescribed GLP-1 Medications in the Veterans Affairs Heart of Texas Health Care Network.

(1-135) Evaluation and Expansion of Pharmacy Services in the Emergency Department at James A. Haley Veterans’ Hospital

(1-136) Pharmacist-Led Approach to Managing Unexpected Urine Drug Screen Results

(1-137) Increasing Utilization of 90-Day Supply Prescriptions for Chronic Medications

(1-138) Development and Implementation of a Weight Management Clinic to Streamline Pharmacist Workflow and Improve Continuity of Care

(1-139) Improving B12 Monitoring in Metformin - Treating Veterans Through an Electronic Health Record Prescribing Prompt

(1-140) Bridging the Gap: Enhancing Access to Long-Acting Injectable Buprenorphine for Veterans in Community-Based Care

(1-141) Pharmacist-Led Immunization Reconciliation in an Inpatient Spinal Cord Injury Unit

(1-142) Implementation of a Computerized Patient Record System (CPRS) Consult to Standardize Medication Therapy Management by Clinical Pharmacist for Post-Lung Transplant Patients

(1-143) Dual Therapy Considerations: Evaluating Tolerability and Optimization of GLP-1 Receptor Agonists for Weight Loss in Combination with Opioids and/or Gabapentinoids

(1-144) Retrospective Review of Vancomycin Dosing and Therapeutic Monitoring in Patients with Spinal Cord Injuries at the Miami VA Medical Center

(1-146) Characterization of the Alcohol Withdrawal Management at the VA Maine Healthcare System

(1-147) Safety Outcomes of Intravenous Iron Therapies: Low Molecular Weight Iron Dextran versus Non-Dextran Iron Products

(1-148) Evaluation of Buprenorphine Response for use in Chronic Pain Treatment

(1-149) Dose Adjustments Following Conversion from Synthroid to Generic Levothyroxine

(1-150) Low Dose Naltrexone for Chronic Pain in the Veteran Population

(1-151) Impact of Penicillin G Benzathine Long-Acting Intramuscular Injection Shortage

(1-152) Diabetes Self-Management Education Integration and Whole Health Initiative at VA Pittsburgh

(1-153) Early Simultaneous Versus Stepwise Implementation of GDMT in Veterans with HFrEF at the Washington DC VA Medical Center: Impact on Clinical Outcomes and Tolerability

(1-154) Pharmacist-Intensivist Collaborative Telehealth for Post-Intensive Care Syndrome in Survivors of Critical Illness: a Pilot Randomized Controlled Trial

(1-155) Comparing Outcomes Between Available Alcohol Withdrawal Treatment Regimens

(1-156) Use of Stress Ulcer Prophylaxis Upon Admission to Intensive Care Units

(1-157) Time to Vasopressor Therapy Initiation and Outcomes in Patients with Hepatorenal Syndrome in the ICU

(1-158) Safety and Efficacy of a Newly Implemented Alcohol Withdrawal Protocol

(1-159) Sodium Bicarbonate Infusion Strategies for Metabolic Acidosis in Critically Ill Patients

(1-160) Nephrotoxin Stewardship: Assessing the Current Nephrotoxin Burden in the Intensive Care Unit

(1-161) Timing of Analgosedation Following Rapid-Sequence Intubation and Its Impact on Intensive Care Unit Outcomes in Veterans

(1-162) Cardiovascular Outcomes with Propofol Compared to Dexmedetomidine in Patients with Heart Failure with Reduced Ejection Fraction

(1-163) Real-World Data on Intravitreal Therapies: Evolution of Prescribing Patterns in a Tertiary Care Hospital (2021–2024)

(1-164) Evaluation of Dronabinol Prescribing for Chronic Pain in a Veterans Healthcare Facility

(1-165) Medication Use Evaluation (MUE) of Glipizide in the Management of Diabetes in Geriatric Veterans at the Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS)

(1-166) Evaluation of Antipsychotic Use for Delirium in a Critical Care Setting

(1-167) Evaluation of Varenicline Treatment in Patients with Tobacco Use Disorder in a Veteran Affairs (VA) Healthcare System

(1-168) Streamlining Supplies: Assessing and Standardizing Prescribing Practices at James A. Haley Veterans’ Hospital

(1-169) Pharmacist-Led Deprescribing Service for Simvastatin when Co-administered with Amlodipine

(1-170) Triptan Prescribing in Cardiovascular or Cerebrovascular Disease

(1-171) Are We Using Trazodone Appropriately? A Retrospective Evaluation of Trazodone Use First-Line for Insomnia in a Veteran Population

(1-172) Evaluation of the Use of Finerenone in Patients with Diabetic Kidney Disease at Veterans Affairs Maryland Health Care System

(1-173) Impact of Rotation from Full μ-Opioid Agonists to Buprenorphine on Pain and Function in Veterans with Chronic Pain

(1-174) Evaluating the Appropriateness of Interleukin 1 Inhibitors for the Management of Gout Flares

(1-175) Assessing the Use of High Dose Opioids Through Retrospective Review at the Veteran's Affairs Butler Healthcare System

(1-176) Evaluation of PCSK9 Inhibitor Usage at the Lebanon Veterans Affairs Medical Center in Comparison to American College of Cardiology 2022 Guidelines

(1-177) Medication Use Evaluation: Evaluation of Sodium–Glucose Cotransporter-2 (SGLT2) Inhibitor-induced Erythrocytosis

(1-178) Tobacco Use Disorder Medication Use Evaluation and Process Improvement Standardizing Referrals for Tobacco Cessation Treatment upon Discharge

(1-179) Evaluating the Utilization of Pharmacogenomic Testing Results in Guiding Statin Prescribing Patterns at Salem VA Health Care System

(1-180) Evaluating Efficacy of High-Dose vs Standard-Dose Influenza Vaccination in Veterans 65 Years of Age and Older

(1-181) Evaluation of Prophylactic Prescribing of Doxycycline After Tick Bites at the Kansas City Veteran Affairs Medical Center (KCVA)

(1-182) Community Living Center Deprescribing Collaborative at Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS)

(1-183) Evaluation of the Inappropriate Use of Aspirin for Primary Prevention of Cardiovascular Disease Among Older Adults In an Outpatient Veterans Affairs Population

(1-184) Impact of VIONE Polypharmacy Review in Medication Deprescribing in a Geriatric Clinic

(1-185) Evaluation of doxepin use and tolerability for sleep in the veteran elderly population

(1-186) Implementation of a Medication Optimization Program in an Outpatient VA Geriatric Oncology Clinic

(1-187) Evaluating the Discontinuation Rates of Semaglutide for Weight Loss in The Geriatric Population at the Minneapolis VA Health Care System

(1-188) Retrospective Evaluation of Levothyroxine Prescribing Trends in Older Veterans

(1-189) Retrospective descriptive analysis of geriatric Veterans started on osteoporosis treatment in the community living center (CLC) at the VA Sierra Nevada Healthcare System.

(1-190) Evaluating The Incidence Of Falls With Zolpidem Monotherapy Versus Concomitant Benzodiazepines In The Elderly Veteran Population

(1-191) Reducing Empiric Broad-Spectrum Antibiotic Coverage for Patients with Hospital Acquired and Ventilator Associated Pneumonia​

(1-192) From Dashboard to HIV PrEP: Pharmacist-Led Outreach to Veterans with Bacterial STI

(1-193) Use of a Standardized Urine Culture Ordering Menu in a Veterans Affairs Medical Center to Optimize Diagnostic Stewardship While Reducing Inappropriate Urine Cultures

(1-194) Retrospective Evaluation of Cystatin C- Guided Vancomycin Dosing in Veterans with Spinal Cord Injury

(1-195) Evaluation of methicillin resistant staphylococcus aureus nasal screening correlation with skin-and-soft-tissue infections within Malcom Randall Veterans Affairs Medical Center

(1-196) Assessment of Clinical Stability and Tolerability in Well-Controlled Adults With HIV Switched to Bictegravir/Emtricitabine/Tenofovir Alafenamide Compared With Continuation of Existing Antiretroviral Therapy

(1-197) Evaluating the Impact of Pharmacist Led Review of Patients on Long-Term Antibiotic Prophylaxis for Recurrent Urinary Tract Infections

(1-198) Evaluation of Vancomycin AUC/MIC Goal Attainment in Patients on Continuous Renal Replacement Therapy Versus Standard Dosing Protocols

(1-199) Evaluation of oral outpatient antibacterial prescriptions exceeding 28-day supply at the Boise VA Medical Center

(1-200) Evaluation of the Efficacy and Safety of Amoxicillin/ Clavulanic Acid Extended-Release for Acute Osteomyelitis at Jesse Brown VA Medical Center

(1-201) Impact of Rapid Blood Culture Identification and Real Time Notification to Pharmacy Service on Antibiotic Optimization

(1-202) Retrospective Analysis of Clostridioides Difficile Infections in Patients Using Proton-Pump Inhibitors in Veterans at VA Central Iowa Health Care

(1-203) Cost-Benefit Analysis of Vancomycin vs Daptomycin for MRSA Infections at VAEKHS

(1-205) Assessment of Positive Urine Culture Follow-Up in Veterans Discharged from the Emergency Department at VA Maine Healthcare System

(1-206) Comparing Incidences of Acute Kidney Injury with Vancomycin and Piperacillin/Tazobactam to Vancomycin and Cefepime in the Veteran Population

(1-207) Local and National PBM Medication Use Evaluation of Non-ICU Community Acquired Pneumonia

(1-208) Pneumococcal Vaccine Uptake and Shared Decision-Making Among Immunocompromised Veterans Aged 65 and Older at VA Sierra Nevada Health Care System (VASNHCS)

(1-209) Penicillin Allergy De-Labeling: Improving Inpatient Antibiotic Selection

(1-210) Impact of Methicillin-Resistant Staphylococcus aureus (MRSA) Nares Polymerase Chain Reaction (PCR) Screening on Vancomycin De-escalation in Skin and Soft Tissue Infections

(1-211) Mapping Antimicrobial Prevalence of Carbapenem-Resistant Enterobacteriales (MAP-CRE)

(1-212) Evaluation of Microbiological and Prescribing Variations in COPD in Rural versus Urban Populations

(1-214) Outcomes of Bacteremia and Efficacy of Standard Cephalosporin Exposure in Obesity

(1-215) An Evaluation of Clinical Outcomes and Resistance in AmpC Producing Infections Treated with a Third-Generation Cephalosporin vs. Piperacillin/Tazobactam

(1-216) Regional Variations in Sputum Microbiota across United States from Veterans with Chronic Obstructive Pulmonary Disease

(1-217) Comparing Acute Kidney Injury Risk: Vancomycin plus Piperacillin-Tazobactam vs. Vancomycin plus Cefepime

(1-218) Impact of EHR Implementation on Antimicrobial Stewardship Outcomes at a Tribal Health Institution

(1-219) Beta Lactam Allergies and Trends in Antibiotic Prescribing in Orthopedic Surgery Patients

(1-220) Impact of Risk Stratified Sepsis Order Sets on Empiric Antibiotic Selection

(1-221) Impact of an Antibiotic Stewardship Intervention on the Utilization of Anti-Pseudomonal Antibiotics for the Treatment of Inpatient Diabetic Foot Infection With or Without Osteomyelitis

(1-222) Implementation of Diagnostic Stewardship Intervention to reduce Inappropriate Ordering of Urine Cultures

(1-223) Fosfomycin for UTIs in males caused by ESBL-E

(1-224) Medication use evaluation of long-term azithromycin use in a veteran population with COPD

(1-225) Reducing unnecessary urine cultures through revised reflex criteria from urinalysis

(1-226) Optimization of the Chronic Obstructive Pulmonary Disease (COPD) Dashboard to Identify Patients with Gaps in Care

(1-227) Integration of a Cognitive Support System Tool into COPD Case Management Workflow at the VA

(1-228) Implementation of Lifestyle Medicine within the Indian Health Service (IHS)

(1-229) Impact of a Pharmacy Review Process on Outpatient Infusion Therapy

(1-231) Clinical Outcomes for Patients Receiving Parenteral Nutrition With Soybean-oil versus Mixed-oil Lipid Injectable Emulsion

(1-232) Assessment of Healthcare Utilization and Adverse Effects in Veterans Receiving Abiraterone Plus Prednisone with Androgen Deprivation Therapy Versus Androgen Deprivation Therapy Alone

(1-233) Optimizing the use of granulocyte colony-stimulating factors for intermediate- and high-risk febrile neutropenia chemotherapy regimens

(1-234) Assessing Clinical Outcomes in Malignant Lymphoma Patients Treated with Dose Rounded Rituximab

(1-235) Evaluating the Role of Clinical Pharmacist Practitioners in Immune Checkpoint Inhibitor Therapy

(1-236) A Quality Improvement Project on Enhancing the Utilization and Education of UGT1A1 Pharmacogenomic Testing Outcomes

(1-237) Evaluating the Appropriateness of Pembrolizumab Prescribing Patterns in the Oncology Outpatient Clinic

(1-238) Evaluation of Transfusion Dependency with Luspatercept in Patients with Myelodysplastic Syndrome

(1-239) Improving Monitoring of Antiandrogen Therapy in an Outpatient Oncology Clinic

(1-240) Evaluation and Comparison of Abiraterone Dosing (250 mg vs 1000 mg) Daily in Prostate Cancer Patients at Cincinnati Veterans Affairs Medical Center (CVAMC)

(1-241) Evaluating the Clinical Impact of Bacillus Calmette-Guerin Shortage on Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer at the Oklahoma City Veterans Affairs Health Care System

(1-242) Utilization of Pharmacy Dose Rounding Procedures for Weight Based Parental Medications and the Effect of Pharmacist Education in a Veterans Affairs Outpatient Infusion Clinic

(1-243) Evaluation of Clinician’s Monitoring of Immune Checkpoint Inhibitors for Safe Use

(1-244) Stay the Course: Oral Androgen Receptor Pathway Inhibitors (ARPIs) Adherence in Veterans with Prostate Cancer Through Multidisciplinary Education

(1-245) Evaluation of Treatment Outcomes in Patients Treated with Opioids Metabolized by Cytochrome P450 2D6 and Antidepressants with Cytochrome P450 2D6 Inhibition

(1-246) Impact of Inpatient Pharmacy Pain Service on Naloxone Distribution

(1-247) Impact of Improved Opioid Patch Documentation in the Inpatient and Long-Term Care Settings

(1-248) Review of the Patterns of Naloxone Kit Prescriptions in Outpatient Settings: Analyzing Indications for 8mg vs 4mg Dosing

(1-249) Overdose Education and Naloxone Distribution via Audio Care Software at Miami VA Healthcare System

(1-250) Assessment of Opioid Reconsideration Clinic at VA Medical Center: Change from Full Agonists to Buprenorphine for Chronic Pain

(1-251) Assessing How Pharmacy-based Counseling on Naloxone Influences Co-Prescribing of Naloxone

(1-252) Development, Implementation, and Utilization of a Substance Use Disorder Menu within a VA Healthcare System

(1-253) Inpatient proactive opioid risk reviews: a one-month pilot

(1-254) Integration of Pharmacogenomic Testing Across Primary Care, Mental Health, Gastroenterology and Oncology

(1-255) Optimizing Antidepressant Therapy for Veterans: The Impact of Pharmacogenomic Testing

(1-256) Implementing Pharmacogenomics (PGx) Testing for Patients Undergoing an Elective Percutaneous Coronary Intervention (PCI) at a Department of Defense (DoD) Facility, A Quality Improvement Project

(1-257) Impact of comprehensive pharmacogenetic medication review on prescribing at Boise VA Medical Center

(1-258) Optimizing Pharmacogenomics: Evaluating the Effectiveness of Pharmacist-Led Group Classes

(1-259) Implementation of Pharmacogenomics Testing Post-Percutaneous Coronary Intervention (PCI) in a Veterans Affairs Medical Center

(1-260) Utilizing Pharmacogenomics Testing to Recommend Statin Retrial at VA Maine in Patients with a History of Statin-Associated Musculoskeletal Symptoms

(1-261) Evaluation of a Pharmacist-Led Pharmacogenomics Intervention to Optimize Statin Therapy and Cardiovascular Health in Veterans

(1-262) A Quality Improvement Project to Increase Pharmacogenomic Testing in Patients Newly Diagnosed with Depression

(1-263) Impact of CYP2C9, ABCG2, and SLCO1B1 Genotype on Rates of Statin-Associated Myopathy in a Veteran Population

(1-264) Pharmacogenomics Utilization as a Tool for Deprescribing in Veterans at High-Risk for Polypharmacy

(1-265) Implementing Pharmacogenomic Testing in a Rural Veteran Population: A Feasibility and Impact Assessment

(1-266) Effectiveness and Safety of Eptinezumab in Real-World Clinical Practice in Patients with Migraine

(1-267) Medication Treatment Disruption and Adverse Mental Health Outcomes in Veterans Using an Antidepressant in Shortage

(1-268) Impact of a Pharmacy-Led VA Headache Clinic on Emergency Department & Urgent Care Utilization, Neurology Access, and Patient Outcomes

(1-269) Journey to Decrease Benzodiazepine Prescribing in a Rural Veteran Affairs Health Care System

(1-270) Investigating Refill Patterns of Vilazodone and Vortioxetine in the Tuscaloosa VA Health System

(1-271) EMPOWERing (Eliminating Medications through Patient OWnership of End Results) Change: A Strategic Approach to Deprescribing Benzodiazepines at the Tuscaloosa VA

(1-272) Bridging the Gap: Evaluating the Underutilization of Medications for Alcohol Use Disorder Among Veterans in Residential Rehabilitation Treatment Programs

(1-273) Evaluation of Discharge Process from a High Intensity Psychiatric Unit at a Veterans Health Care System

(1-274) Evaluating Use of Medications for Alcohol Use Disorder in the Comprehensive Outpatient Substance Abuse Treatment (COSAT) Clinic

(1-275) Assessing the Risk for Suicidality in Veterans Receiving GLP-1 Receptor Agonists at the Veterans Affairs Central California Health Care System

(1-276) Evaluation of Antipsychotic Use in Veterans with Dementia at a VA Medical Center – An Assessment Based on the APDEM1 Metric

(1-277) Reviewing Depressive Effects of Glucagon-Like-Peptide-1 Receptor Agonists with Veterans Enrolled in a Mental Health Clinic

(1-278) Evaluation of Veteran Eligibility for Ketamine/Esketamine Treatment in Patients with Treatment-Resistant Depression Presenting to Mental Health Outpatient Clinics at the VA Connecticut Healthcare System

(1-279) Evaluating Utilization of Acamprosate in a Veterans Affairs Healthcare System

(1-280) Comparative Effects of Brexpiprazole Versus Risperidone on Lipid Profiles

(1-281) Review to Assess the Compliance in Patients Currently on Lithium Therapy at the Miami VA

(1-282) Hyponatremia Related to Selective Serotonin Reuptake Inhibitors versus Serotonin-Norepinephrine Reuptake Inhibitors

(1-283) Optimizing Tardive Dyskinesia Monitoring: Development and Implementation of a Pharmacist-Led AIMS Monitoring Dashboard and Clinic for Veterans Receiving Antipsychotics

(1-284) Evaluation of Patients receiving Glucagon-like Peptide 1 Based Injectable Therapies and a Reduction of Alcohol Use Disorder in Four Veterans Affairs Medical Centers

(1-285) Treatment of Neuropathic Pain at the Boise VAMC

(1-286) Evaluation of Clozapine Prescribing at Veterans Health Administration (VHA) Before and After Rescinding Monitoring Directive

(1-287) Outcomes of Non-Renally Dose-Adjusted Paliperidone Long-Acting Injectables in the Inpatient Setting at Jesse Brown VA Medical Center

(1-288) Evaluating the Efficacy of Metformin vs. GLP-1 Agonists for Metabolic Syndrome in Patients on Atypical Antipsychotics at a Veterans Affairs Medical Center

(1-289) Impact of a Psychiatric Clinical Pharmacist Practitioner on Clinical Outcomes and Routine Monitoring Associated with Long-Acting Injectable Administration at Jesse Brown VA Medical Center

(1-290) Medication Use Evaluation: Lithium Monitoring at Jesse Brown VA Medical Center

(1-291) Enhancing Clozapine Utilization Through Pilot Clozapine Program Development at Southeast Louisiana Veterans Healthcare System (SLVHCS)

(1-292) A Pharmacist-Led Initiative to Improve Stimulant Monitoring Compliance in Veterans at the Boston Veteran Affairs Healthcare System

(1-293) Evaluating the Impact of Clinical Efficiency Tools on Completion of Antipsychotic Glucose Monitoring

(1-294) A Comparative Analysis of Methadone Versus Buprenorphine/Naloxone Treatment Retention Rates Among Patients With Opioid Use Disorder in the Veterans Affairs New Jersey Health Care System

(1-295) Assessing the Safety and Efficacy of Intranasal Esketamine for Treatment-Resistant Depression (TRD) in Veterans with a History of Substance Misuse

(1-297) Evaluating Pharmacy Student Contributions to Mental Health Care at the Veterans Affairs Caribbean Healthcare System (VACHS)

(1-298) Evaluation of Tobacco Use Screening Reminder Completion During Admission to an Inpatient Psychiatric Ward

(1-299) The Effect of a Mental-Health Pharmacist-Led Post Discharge Engagement (PDE) Clinic on Outpatient Mental Health Outcomes Following an Inpatient Psychiatric Hospital Admission

(1-300) Change in AUDIT-C Score Following GLP-1 Receptor Agonist Use: A Retrospective Review

(1-301) Evaluation of Appropriate Z-Drug Prescribing and Deprescribing at a Large VA Medical Center

(1-302) Naltrexone for Management of ‘Kratom Use Disorder’ in a Patient with Concurrent Alcohol Use Disorder

(1-303) The Association of Refills of Medications for Alcohol Use Disorder at Discharge with Rates of Readmission in Alcohol Use Disorder

(1-304) Impact of pharmacist-led education and medication algorithm on discharge prescribing for alcohol use disorder

(1-305) Evaluation of Pharmacogenomic Impact on Prescribing of Psychiatric Medications

(1-306) Impact of Clinical Pharmacists on Cost Avoidance in Epilepsy Clinic

(1-307) Real-World Impact of Respiratory Syncytial Virus Vaccination: Outcomes in Emergency Department Patients at Veterans Affairs Connecticut Healthcare System

(1-308) Pharmacist’s Role in Expanding Harm Reduction Services at an Indian Health Service Facility

(1-310) Impact of Beyfortus® Vaccination Rates & Respiratory Syncytial Virus Severity in the Native American Pediatric Population

(1-311) Database Rapid Cycle Analysis (RCA) of Multiple Respiratory Syncytial Virus (RSV) Vaccine Administrations in the Veterans Health Administration (VHA)

(1-312) Evaluation of Pharmacy-Driven Culture Callback Protocol on Antimicrobial Therapy Optimization

(1-313) Interdisciplinary Approach to Increasing Protection in Native American Children Against RSV in a Rural AZ Community

(1-314) Addressing Post-Acute Withdrawal: Implementation of a Defined Protocol to Improve Outcomes for Alcohol Use Disorder

(1-315) Developing the Role of Clinical Pharmacy Technicians at the Outpatient Pharmacy Intake Window

(1-316) Implementation of a Urology Clinic Medication Order Set

(1-317) Improving Hepatitis B (HBV) Vaccination among Veterans through Expanded Use of HepB-CpG

(1-318) Implementation of an Outpatient Psychotropic Medication Order Set

(1-319) Evaluating Utility of the Buprenorphine Prior Authorization Drug Request at the Orlando VA

(1-320) Impact of Interdisciplinary Chart Reviews following Emergency Department or Hospital Admission due to Alcohol-involved Non-fatal Overdoses

(1-321) Implementation of Interdisciplinary Overdose Review Team Recommendations at the Bay Pines VA Healthcare System

(1-322) Returned Mailed Medications in an Outpatient VA Pharmacy: A Quality Improvement Approach to Reduce Waste

(1-323) Transforming Care: Assessing the Role and Impact of Clinical Pharmacist Practitioners through Electronic Consult Services

(1-325) Evaluating the Impact of Clinical Pharmacy Practitioner (CPP) Patient Aligned Care Team (PACT) Services on Type 2 Diabetes Management in Veterans Transitioned from Community Care

(1-326) Improving Completion of Cardiometabolic Monitoring for Patients on Second Generation Antipsychotics

(1-327) Medication Use Evaluation of the Ticagrelor (Brilinta®) Qualification Note at the Harry S. Truman Memorial Veterans’ Hospital

(1-328) Evaluation of Type II Diabetes Mellitus Control with Continuous Glucose Monitoring Versus Blood Glucose Monitoring in a Veteran Population

(1-329) Evaluating the Appropriateness of Continued Therapy for Patients on Chronic Weight Management Medications

(1-330) Glucose Improvement Post Continuous Glucose Monitoring Expansion in a Veteran Population

(1-331) Population Health Management for Patients with Cardiovascular Risk – Innovative Integration of Learners to Efficiently Optimize Patient Care

(1-332) Evaluation of Changes to the Medication Use Processes from Cart Fill to Automated Dispensing Cabinets for an Inpatient Psychiatric Unit and Long-Term Care Facility

(1-334) Impact of Deprescribing Tool Use in Older Adults at VA Caribbean Healthcare System (VACHS) Mental Health Clinics

(1-335) Optimizing Gabapentin Use in a Tertiary Care Teaching Hospital: A Pharmacist-led Initiative

(1-336) Evaluation of Institutional Denosumab Monitoring in Patients with Osteoporosis

(1-337) Evaluating the Use of a Digital Platform for Pain Assessment Completion in a Pharmacist-Led Pain Clinic within a Veterans Affairs Health Care System

(1-338) Assessment of Concomitant Prescribing Patterns of DPP-IV Inhibitors and GLP-1 RA Therapy at a Veterans Affairs Medical Center

(1-339) Pharmacist Driven Renal Dose Optimization of Antibiotics via Standing Order in a Veterans Affairs Healthcare System

(1-340) Identification of Proper Monitoring in Patients on High Risk QTc Prolonging Agents

(1-341) Appropriateness of Single Dose Intravenous Vancomycin in Patients Discharged from the Emergency Department at a Veterans Affairs Hospital

(1-342) Admission Medication Reconciliation Template Implementation at VA Puget Sound Health Care System (VAPSHCS)

(1-343) Retrospective Review of Heparin Efficacy in Patients with Cardiovascular Indications Managed with Standardized Defense Health Agency Protocols

(1-344) Optimization of Supply Item Inventory by Increasing Mail Order Utilization at the VA Puget Sound Outpatient Pharmacy

(1-345) Optimizing Pharmacy-Led Vaccination Initiatives at a Tribal Health Care Organization

(1-346) Understanding the Use and Impact of Capsaicin 8% Patches: A Patient-Centered Study on Efficacy, Adverse Effects, and Repeat Usage

(1-347) Patient Outcomes at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS) from VA Formulary Switch from Adalimumab to Adalimumab-bwwd

(1-348) Adalimumab Persistence within a Pharmacist-Led Centralized Specialty Medication Management Clinic

(1-349) Assessing the Impact of Short-Term App-Based Intervention on Long-Term Compliance and Patient Outcomes in Veterans with Uncontrolled Non-Insulin Dependent Diabetes: A Mixed Methods Follow-Up Study

(1-350) Vaccine-Induced Modulation of Panel reactive Antibodies: Consequences on Transplant Candidacy (Vaccine IMPACT)

(1-351) Evaluation of weight reduction after switching from maximum dose semaglutide to tirzepatide at Bay Pines Veterans Affairs Healthcare System

(1-352) Assessing Whole Health Interventions to Promote Wellness and Prevent Burnout in Pharmacy Residents

(1-353) Evaluating The Risk of Hypertension Exacerbation in Women Taking Combined Oral Contraceptives with a Pre-Existing Diagnosis of Hypertension

(1-354) Evaluation of a Pharmacist-Led Health Disparity Initiative to Analyze Statin Adherence Metrics in Female Patients at the Miami VA Healthcare System

(1-355) Multidisciplinary Standardization for Compliance with United States Pharmacopeia <797> Standards in a Native American Health Care Facility